COVID-19 Vaccine & Treatment Research
Researchers in the Vaccine Center lead NYU Langone’s efforts to develop new vaccines and treatments for COVID-19.
NYU Langone Launches Two Major Clinical Trials for COVID-19 Vaccine and Antibody Treatment
Led by Mark J. Mulligan, MD, in collaboration with the University of Maryland, Pfizer Inc., and BioNTech SE, the vaccine clinical trials test whether four experimental messenger RNA (mRNA) vaccine candidates can prevent COVID-19 infection. The vaccines are being developed by Pfizer and BioNTech, which recently launched a similar first-in-human trial in Germany.
Concurrently, the NYU Langone team is working with Eli Lilly and Company to treat its first patients with an antibody therapy designed to safely reduce COVID-19 severity. The experimental treatment consists of identical copies of an antibody, a blood protein related to those that occur naturally as part of the human immune system. Eli Lilly and Company announced the trial’s start on June 1, 2020. NYU Grossman School of Medicine is among the first centers to enroll patients nationally.
For more information about our COVID-19 vaccine trials, watch a video of a town hall meeting on COVID-19 vaccines hosted by NYU Long Island School of Medicine.
Para información sobre el ensayos de vacunas contra la COVID-19 en el Vaccine Center, para ver un video de Padre latino se une al estudio clínico para vacuna contra el COVID-19 de Pfizer y el artículo “Miedo y esperanza: así es ser voluntario de una vacuna del coronavirus” en El Tiempo.
Participate in a COVID-19 Clinical Trial
We are actively recruiting participants for our COVID-19 clinical trials. Learn more about how to participate.